Bellicum Pharmaceuticals Finalizes Sale and Approves Dissolution

Bellicum Pharmaceuticals (BLCM) has released an update.

Bellicum Pharmaceuticals, Inc. has finalized the sale of its research and development programs, including the CaspaCIDe safety switch and the dual-switch GoCAR-T technology, to The University of Texas M. D. Anderson Cancer Center for $8.1 million. Following a lack of quorum at the initial special meeting, a reconvened meeting saw stockholders approve both the asset sale and the company’s dissolution. The successful vote paves the way for the company to liquidate and dissolve, as outlined in the approved Plan of Dissolution, subject to legal and regulatory obligations.

For further insights into BLCM stock, check out TipRanks’ Stock Analysis page.